Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | RHOC | P08134 | 1/20 | 0.38 |
| ▸ | RHOA | P61586 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6405971 | 0.85 | EPHX2 (0.43) | CNR1NOS1NOS2EPHX2RHOC | |
| SCHEMBL4711912 | 0.85 | CNR1 (0.50) | CNR1ENPP2NOS1NOS2TP53 | |
| SCHEMBL22495140 | 0.79 | PAK1 (0.43) | CNR1NOS1NOS2EPHX2RHOC | |
| SCHEMBL22495122 | 0.76 | HCAR3 (0.59) | SMN1; SMN2 | |
| SCHEMBL4717960 | 0.73 | NOS2 (0.52) | CNR1NOS1NOS2TP53SMN1; SMN2 | |
| SCHEMBL27506229 | 0.72 | DCTPP1 (0.52) | SMN1; SMN2CYP2C9 | |
| SCHEMBL11259285 | 0.72 | GAA (0.49) | CYP2C9 | |
| SCHEMBL27626141 | 0.72 | POLB (0.61) | EPHX2RHOCRHOATP53SMN1; SMN2 | |
| SCHEMBL16485928 | 0.72 | SPR (0.43) | NOS1NOS2EPHX2RHOCRHOA | |
| SCHEMBL1859729 | 0.71 | KDM1A (0.37) | EPHX2SMN1; SMN2PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101587-A9 | Method for treating allergies using substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICALS, INC. | 2005-05-12 | — | — | US | disclosed |
| US-20020055497-A1 | Method for treating allergies using substituted pyrazoles | BUTLER CHRISTOPHER R (US) | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101587-A9 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | CNR1 1665/4885ENPP2 724/4885NOS1 575/4885 |
| US-20020055497-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | CNR1 1665/4885ENPP2 724/4885NOS1 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.